{"filings":[{"id":1027290,"accession_number":"0001193125-26-269358","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-06-12T20:05:16+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xilio rebalances board classes, shareholders approve stock plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel Curran re-elected Class II director, then resigned and reappointed Class III to equalize board classes; no compensation change.","Stockholders approved Amended and Restated 2021 Stock Incentive Plan, adding prefunded warrant shares to annual evergreen increase.","All four Class II director nominees and ratification of Ernst & Young as auditor approved at June 10, 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22525,"accession_number":"0001193125-26-218194","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-05-12T11:35:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio Q1 net loss $9.5M; cash $150.3M; XTX501 IND planned mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $150.3M at Mar 31, 2026 (vs $137.5M Dec 31, 2025); runway into early 2028.","Net loss $9.5M vs $13.3M YoY; collaboration revenue $12.6M (up from $2.9M); R&D $19.8M (up from $8.3M).","Achieved $6.0M development milestone under AbbVie collaboration (Q2 2026).","XTX501 IND submission planned mid-2026; Phase 1 start H2 2026; initial data H2 2027.","Appointed Cheryl R. Blanchard, Ph.D. to board of directors (April 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":12648000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96082,"accession_number":"0001193125-26-157940","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xilio Therapeutics appoints Cheryl Blanchard to Board; Rossi resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cheryl Blanchard elected as Class III director effective April 15, 2026; term expires at 2027 annual meeting.","Blanchard appointed chair of Compensation Committee and member of Audit Committee.","Blanchard receives $40k annual cash retainer, $12k for Comp chair, $7.5k for Audit; initial option for 10k shares vesting over 3 years.","Christina Rossi resigned from Board on April 15, 2026; resignation not due to any disagreement with company.","Board adopted amended Non-Employee Director Compensation Policy effective April 15, 2026 (Exhibit 10.1)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109676,"accession_number":"0001193125-26-118544","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio announces Q4 net income $10.4M, cash $137.5M, runway through 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $10.4M in Q4 2025 vs net loss of $13.1M in Q4 2024; full year net loss narrowed to $35.0M from $58.2M.","Cash and cash equivalents $137.5M at Dec 31, 2025, up from $55.3M end of 2024; cash runway extended through end of 2027.","XTX501 (bispecific PD-1/masked IL-2) on track for IND submission mid-2026 and Phase 1 start H2 2026; initial data expected H2 2027.","Advancing masked T cell engagers: CLDN18.2 program preclinical data at AACR April 2026; PSMA/STEAP1 candidate nomination Q2 2026.","Recent capital raises: $35.8M from Series B warrant exercises (Jan 2026) and $40.0M follow-on offering (Feb 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109675,"accession_number":"0001193125-26-103150","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Effective 5:00 p.m. ET on March 13, 2026; trading on split-adjusted basis starts March 16 under ticker XLO.","Outstanding shares reduce from ~73.5M to ~5.2M; authorized shares and par value unchanged.","Purpose is to increase per-share price to meet Nasdaq minimum $1.00 bid requirement.","No fractional shares issued; stockholders receiving cash in lieu of fractional shares.","Stockholders approved reverse split at Special Meeting held February 23, 2026; ratio set by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109674,"accession_number":"0001193125-26-097603","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xilio Therapeutics posts corporate investor presentation; no new data in filing excerpt","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck titled 'Unlocking the Potential of Immuno-Oncology Therapies' dated March 9, 2026.","Presentation made available on company's website; no specific pipeline or financial details provided in this extract.","Regulatory filing solely covers Reg FD disclosure of routine investor materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109673,"accession_number":"0001193125-26-065234","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xilio Therapeutics stockholders approve reverse stock split at ratio from 1:2 to 1:30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio between 1:2 and 1:30, board to set exact ratio and timing.","Proposal passed with 55,438,144 votes for, 1,521,271 against, 33,539 abstaining, no broker non-votes.","Adjournment proposal also approved with 55,461,067 for, 1,491,733 against, 40,154 abstaining.","Special meeting held on February 23, 2026; both proposals received overwhelming stockholder support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109672,"accession_number":"0001193125-26-048942","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Xilio Therapeutics prices $40M pre-funded warrant offering; lead investor Coastlands Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pre-funded warrants to purchase 74,780,300 common shares at $0.5349/warrant; exercise price $0.0001/share.","Gross proceeds ~$40M; net proceeds ~$37.1M after underwriting discounts and offering expenses.","Offering led by Coastlands Capital with participation from Gilead, OrbiMed, Perceptive Advisors.","Expected closing date February 13, 2026; net proceeds for product development and general corporate purposes.","Pre-funded warrants immediately exercisable; beneficial ownership capped at 4.99% (holder can elect up to 19.99%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109671,"accession_number":"0001193125-26-007063","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Xilio reports $137.5M cash, appoints chair, gets $35.8M from warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $137.5M at Dec 31, 2025, including $35.8M from Series B warrants; runway into Q2 2027.","Full exercise of Series B warrants by Coastlands Capital, Frazier Life Sciences, and Gilead.","Achieved milestone for masked antibody program under AbbVie; nominated CLDN18.2 T cell engager candidate.","Appointed Sara Bonstein as board chair, succeeding Paul Clancy who retired Jan 6, 2026.","Pipeline milestones: IND for XTX501 mid-2026, initial Phase 1 data H2 2027, STEAP1 candidate H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109670,"accession_number":"0001193125-26-001580","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.","As of Jan 2, 2026, 67.5M shares of common stock outstanding.","48.2M Series C warrants outstanding at $0.75 strike; if fully exercised could add $36.2M gross.","Existing cash plus net proceeds from Series B exercise expected to fund operations into Q2 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126201,"accession_number":"0001193125-25-297165","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 2025 equity plan and executive option repricing to $1.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 Stock Incentive Plan approved with 30.5M for, 2.9M against.","CEO René Russo's 2,198,212 options repriced from $5.76 to $1.50.","CFO Christopher Frankenfield's 848,172 options repriced from $4.67 to $1.50.","CMO Katarina Luptakova's 225,210 options repriced from $4.10 to $1.50; effective after market close Nov 21."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126200,"accession_number":"0001193125-25-278835","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio Q3 net loss $16.3M; cash $103.8M; vilastobart 40% ORR in MSS mCRC subset","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.3M for Q3 2025 vs $14.0M in Q3 2024; collaboration revenue $19.1M (up from $2.3M YoY).","Cash $103.8M at Sep 30, 2025; plus $17.5M milestone from Gilead in Q4; runway into Q1 2027.","Vilastobart Phase 2 data: 40% ORR in heavily pretreated MSS mCRC without liver metastases and high plasma TMB (≥10 mut/Mb).","Efarindodekin alfa Phase 1 data showed monotherapy activity; RP2D selected; $17.5M milestone from Gilead achieved.","XTX501 IND planned mid-2026; masked T cell engagers advancing with PSMA, CLDN18.2, STEAP1 candidates."],"consensus_eps_estimate":-0.4242,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":30080000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126199,"accession_number":"0001193125-25-271189","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xilio reports 40% ORR in MSS mCRC with high plasma TMB; advances masked T cell engager programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vilastobart + atezolizumab: 40% ORR in heavily pre-treated MSS mCRC without liver mets and high plasma TMB (≥10 mut/Mb); p=0.05 correlation.","Estimated 55% of MSS CRC patients have high plasma TMB via Guardant360 assay, vs <10% by tissue TMB.","Preclinical masked T cell engagers show reduced systemic toxicity and enhanced durability with costimulation; PSMA candidate nominated Q3 2025.","Phase 1 efarindodekin alfa: well-tolerated at >100-fold MTD of rhIL-12, 2 PRs in advanced solid tumors, immune infiltration.","Vilastobart ctDNA data: deep reductions associated with response; 2 patients achieved endoscopic CR with undetectable ctDNA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126198,"accession_number":"0001193125-25-229231","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xilio Therapeutics transfers to Nasdaq Capital Market; extended bid price deadline to March 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received approval on Oct 2, 2025 to transfer listing from Nasdaq Global Select to Capital Market, effective Oct 6.","Transfer follows failure to meet $1.00 minimum bid price requirement for continued Global Select listing.","Nasdaq granted additional 180-day period until March 30, 2026 to regain compliance with minimum bid price.","Stock must close at $1.00+ for 10 consecutive business days to regain compliance; company evaluating options.","Common stock continues to trade under symbol XLO on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142928,"accession_number":"0001558370-25-011949","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xilio starts Phase 2 XTX301 (IL-12), gets $17.5M milestone from Gilead; cash extended to Q1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated patient dosing in Phase 2 of efarindodekin alfa (XTX301) for advanced solid tumors; RP2D selected.","Achieved $17.5M development milestone under Gilead license agreement; expects payment in Q4 2025.","As of June 30, 2025, cash and equivalents $121.6M; plus milestone extends cash runway into Q1 2027.","Phase 1 data: two partial responses (1 confirmed, 1 unconfirmed) in late-line advanced solid tumors; generally well-tolerated.","Gilead can elect to transition development after specified clinical data package for a $75M fee; Xilio eligible for up to $500M in milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142927,"accession_number":"0001558370-25-011802","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xilio Therapeutics receives second Nasdaq deficiency letter for low stockholders' equity; bid price also non-compliant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of $7.069M as of June 30, 2025, below $10M minimum required for Nasdaq Global Select Market.","Company has 45 days (until Oct 6, 2025) to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Also remains out of compliance with $1.00 minimum bid price requirement, initial cure period expires Oct 1, 2025.","No immediate effect on listing; company may also seek transfer to Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142926,"accession_number":"0001558370-25-011473","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio Q2 net loss $15.8M, cash $121.6M; pipeline progress on vilastobart and masked T cell engagers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.8M in Q2 2025 vs $13.9M a year ago; cash and equivalents $121.6M vs $55.3M at Dec 31, 2024.","Vilastobart Phase 2 data at ASCO: 26% objective response rate in heavily pre-treated MSS CRC patients without liver metastases.","On track to nominate first development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) in H2 2025.","June 2025 follow-on offering raised ~$50M gross; up to $100M additional from warrants if exercised at $0.75 per share.","Cash runway expected through end of Q3 2026 based on current plans."],"consensus_eps_estimate":-1.1312,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":11014000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161011,"accession_number":"0001558370-25-008571","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xilio stockholders elect Class I directors, approve 3x share increase and officer exculpation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["René Russo (32.5M), Sara Bonstein (32.4M), James Shannon (31.0M) elected Class I directors.","Share increase amendment approved: 38.8M for (95.1%), increasing authorized common from 200M to 600M shares; filed June 10.","Officer exculpation amendment approved: 32.3M for (99.3%); filed June 10.","Ernst & Young ratified as auditor for FY2025: 40.7M for (99.7%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161010,"accession_number":"0001558370-25-008512","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xilio Therapeutics elects Dr. Akintunde Bello to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to ten directors; Dr. Bello elected as Class II director effective June 10, 2025.","Term expires at 2026 annual meeting; appointed to Nominating and Corporate Governance Committee.","Compensation follows standard non-employee director terms as described in the 2025 proxy statement.","Dr. Bello will enter into the company's standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161009,"accession_number":"0001193125-25-133773","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Xilio Therapeutics prices $50M public offering of warrants; cash runway through Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of ~$46.6M from offering of pre-funded warrants and Series A/B/C warrants, priced at $0.7499 per unit.","Cash runway extended to Q3 2026, assuming no contributions from AbbVie or Gilead partnerships.","Series A warrants exercisable after Dec 1, 2025 or if stock closes above $1.50 for five days; $0.75 exercise price.","Series B and C warrants subject to offset/cancellation if non-dilutive capital ≥$20M received before Dec 1, 2026.","If all Series B and C warrants exercised for cash, additional gross proceeds up to ~$100M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161008,"accession_number":"0001193125-25-132710","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.","Differentiated safety: only 7% colitis (3/44), low discontinuation (5%); combination well-tolerated.","Patient with liver metastasis from Phase 1C on treatment >14 months; 150mg Q6W dose cleared and cohort enrolling.","Xilio seeking partnership for vilastobart to accelerate development; additional data expected H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161007,"accession_number":"0001558370-25-006852","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports Q1 net loss $13.3M, cash $89.1M; AbbVie deal provides $52M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.3M for Q1 2025, vs $17.2M Q1 2024.","Cash $89.1M as of Mar 31, 2025, up from $55.3M at Dec 31, 2024, driven by $52M AbbVie upfront.","R&D expenses $8.3M (down from $10.4M); G&A $8.5M (up from $6.1M) year-over-year.","Updated Phase 2 data for vilastobart + atezolizumab in MSS CRC to be presented at ASCO 2025 (abstract 3553).","First development candidates for masked T cell engagers (PSMA, CLDN18.2, STEAP1) expected H2 2025–H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":2930000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161006,"accession_number":"0001558370-25-004599","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-04-08T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xilio receives Nasdaq bid-price deficiency letter for shares below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated April 4, 2025; stock closed below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until Oct 1, 2025) to regain compliance.","To cure, bid price must close at or above $1.00 for at least 10 consecutive business days.","If not cured, Xilio may transfer to Nasdaq Capital Market for an additional 180-day period.","No immediate effect on listing; company evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179203,"accession_number":"0001193125-25-051532","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xilio Therapeutics enters into $50M ATM equity offering with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Xilio entered into Sales Agreement with Leerink Partners to sell up to $50M of common stock via ATM offering.","Agent Leerink will receive 3.0% commission on gross proceeds from any shares sold under the agreement.","Sales will be made on Nasdaq Global Select Market under effective S-3 registration statement filed Nov 2022.","No minimum sales obligation; company retains discretion over timing and amount of any sales.","The ATM facility was established on March 11, 2025; either party may terminate upon written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179202,"accession_number":"0001193125-25-051441","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports Q4/FY 2024 results; cash $55.3M, AbbVie collaboration adds $52M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.1M in Q4 2024, $58.2M for FY 2024; license revenue $6.3M from Gilead deal.","Cash $55.3M at Dec 31, 2024; plus $52M AbbVie upfront in Q1 2025 extends runway into Q1 2026.","Vilastobart Phase 2 in MSS CRC: 27% ORR in patients without liver metastases; colitis 5%.","Collaboration with AbbVie: up to $2.1B total payments plus royalties; develop masked T cell engagers.","Plan to nominate development candidates for PSMA (Q3 2025), CLDN18.2 (Q4 2025), STEAP1 (H1 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179201,"accession_number":"0001558370-25-000823","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Xilio signs AbbVie deal: $52M upfront, up to $2.1B milestones for masked T-cell engagers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $52M ($42M cash + $10M equity at $2.30/shr); AbbVie gets options for 4 masked TCE programs and license for masked antibody.","Contingent payments up to ~$2.1B in option fees and milestones plus tiered mid-to-high single-digit royalties.","Xilio announces three wholly-owned preclinical masked TCE programs targeting PSMA, CLDN18.2, STEAP1 with candidate nomination timelines through 2027.","Cash runway extended into Q1 2026 with upfront payments; additional milestones require further capital.","Collaboration validates Xilio's tumor-activation platform; CEO highlights potential to improve TCE tolerability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179200,"accession_number":"0001558370-25-000291","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xilio reports 27% response rate for vilastobart + atezolizumab in MSS CRC Phase 2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27% preliminary ORR (3 PRs, 2 confirmed) in MSS CRC patients without liver metastases as of Jan 13, 2025 cutoff.","Responses accompanied by decreases in CEA and ctDNA levels and clinical symptom improvement.","Safety: well-tolerated; 5% colitis, low Grade 3/4 irAEs, no treatment-related deaths.","Heavily pre-treated population: 70% had ≥3 prior lines of therapy.","Company plans to seek partnerships; expects to report updated Phase 2 data mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195888,"accession_number":"0001558370-24-016372","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"Xilio completes $25M Gilead investment; XTX301 shows no DLTs in Phase 1; cash into Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed $8.2M Gilead private placement (common + prefunded warrants), exhausting $25M stock purchase agreement.","Preliminary Phase 1 data for XTX301 (IL-12) in 34 patients: no DLTs, no Grade 4/5 AEs, sustained IFN-gamma signaling.","No measurable activated XTX301 in peripheral circulation; majority of AEs Grade 1/2 (flu-like, CRS, transaminitis).","Cash runway guidance updated: existing cash + equivalents expected to fund operations into Q3 2025.","Initial Phase 2 data for vilastobart (XTX101) + atezolizumab in MSS CRC to be presented at ASCO GI (Jan 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195887,"accession_number":"0001558370-24-014773","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Xilio Q3 net loss $14.0M; Phase 1C vilastobart + atezolizumab shows partial responses in cold tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash $61.3M as of Sept 30, 2024; cash runway through Q2 2025.","Phase 1C: 2 unconfirmed PRs (MSS CRC with liver lesion resolution, ampullary carcinoma); no Grade 4/5 treatment-related AEs.","RP2D selected: vilastobart 100 mg Q6W + atezolizumab 1200 mg Q3W; Phase 2 enrolling MSS CRC.","Initial Phase 2 data for vilastobart combo in ~20 MSS CRC patients expected Q4 2024; ~40 total by Q1 2025.","License revenue $2.3M from Gilead agreement; net loss $14.0M vs $16.7M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212164,"accession_number":"0001558370-24-012775","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xilio Therapeutics receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 10, 2024; common stock bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days until March 10, 2025 to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, may transfer to Nasdaq Capital Market for additional 180-day period, subject to other listing standards.","Company monitoring bid price and evaluating options; no assurance regaining compliance will be achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212163,"accession_number":"0001558370-24-011470","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio Q2 net loss $13.9M; initiates Phase 2 for XTX101 in MSS CRC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.9M in Q2 2024 vs $19.4M in Q2 2023; R&D expenses $11.2M.","Cash and equivalents $74.9M at June 30, 2024 (up from $44.7M Dec 2023); runway into Q2 2025.","Initiated Phase 2 trial of XTX101 + atezolizumab in MSS CRC; data expected Q4 2024.","Phase 1B dose expansion for XTX301 started; Phase 1A dose escalation ongoing with no DLTs.","Promoted Chris Frankenfield to CFO while continuing as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":2357000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231061,"accession_number":"0001558370-24-009247","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xilio Therapeutics stockholders elect Clancy and Rossi as Class III directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Paul J. Clancy and Christina Rossi as Class III directors each with ~94.4% of votes cast (excluding broker non-votes).","Auditor Ernst & Young ratified with 26,199,617 votes for (99.6% of votes cast).","Broker non-votes of 6,783,293 on director election; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231060,"accession_number":"0001558370-24-009138","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xilio Therapeutics expands board to nine with two new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to nine directors; elected James Shannon, M.D. as Class I director (term expiring at 2025 annual meeting).","Elected Aoife Brennan, M.D. as Class III director (term expiring at 2027 annual meeting).","Dr. Shannon appointed to Nominating and Corporate Governance Committee; Dr. Brennan to Audit Committee.","Both directors to receive standard non-employee director compensation and enter standard indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231059,"accession_number":"0001558370-24-008063","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio Q1 net loss $17.2M; Gilead deal funds cash runway into Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.2M in Q1 2024 vs $22.6M YoY; cash and equivalents $34.0M at March 31.","In April 2024 received $30M upfront + $13.5M equity from Gilead; up to $592.5M in potential milestones.","Plan to initiate Phase 2 trial for XTX101 (anti-CTLA-4) in MSS CRC in Q3 2024; data in Q4 2024.","Discontinued XTX202 monotherapy; exploring combo development opportunities.","Cash runway expected into Q2 2025, including $44.6M in April gross proceeds from Gilead and private placements."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231058,"accession_number":"0001558370-24-004528","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports FY2023 net loss of $76.4M, Gilead licenses XTX301 for up to $604M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents were $44.7M at Dec 31, 2023, down from $120.4M a year earlier.","Net loss was $17.7M for Q4 2023 and $76.4M for FY2023, vs $22.5M and $88.2M in 2022.","Gilead pays $43.5M upfront ($30M cash + $13.5M equity) for exclusive license to XTX301; Xilio eligible for up to $604M in milestones and tiered royalties.","Plans to initiate Phase 2 trial of XTX101 + atezolizumab in MSS CRC in Q3 2024, with initial data in Q4 2024.","Cash runway extended into Q2 2025 after Gilead upfront, $11.3M private placement, and workforce reduction of ~21%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249464,"accession_number":"0001558370-24-004249","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xilio Therapeutics issues 6.86M shares to Gilead at $1.97/share for $13.5M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 6,860,223 shares to Gilead Sciences at $1.97/share for ~$13.5M.","Shares issued under an exclusive license agreement previously disclosed.","Shares outstanding increased from 27,613,263 to 34,473,486.","Placement closed on March 28, 2024, as part of strategic collaboration with Gilead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249463,"accession_number":"0001558370-24-004165","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","2.02","8.01","2.05","3.02","7.01","9.01"],"status":"ready","headline":"Xilio licenses XTX301 to Gilead for $43.5M upfront, up to $604M total; raises $11.3M, cuts 21% workforce","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive global license to Gilead for tumor-activated IL-12 XTX301; Xilio receives $43.5M upfront (cash + equity), potential $604M milestones and tiered royalties.","XTX301 Phase 1 ongoing; Gilead can opt in after Phase 2 data for $75M transition fee; Xilio responsible through initial dose expansion.","Private placement of $11.3M from existing investors at $0.64/share; prefunded warrants at $0.6399; gross proceeds ~$11.3M.","Restructuring: cut 15 employees (21% workforce), discontinue XTX202 monotherapy, focus on XTX301 and XTX101; expects ~$1.0M one-time severance costs.","Preliminary cash $44.7M at 12/31/23; repaid PacWest loan; cash runway into Q2 2025 with Gilead upfront and financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249462,"accession_number":"0001558370-24-000383","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-01-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xilio receives Nasdaq deficiency notice for bid price below $1.00/share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Bid price closed below $1.00 for 30 consecutive business days; violates Minimum Bid Requirement.","180-day cure period expires July 17, 2024; must trade at $1.00+ for 10 consecutive days to regain compliance.","May be eligible for extra 180-day period if transfer to Nasdaq Capital Market; no guarantee of success.","Company will monitor bid price and evaluate options; potential delisting risk remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249461,"accession_number":"0001558370-24-000031","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2024-01-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xilio Therapeutics grants 177,000 RSUs to CEO and 20,000 RSUs to SVP in annual equity awards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO René Russo granted 177,000 restricted stock units effective Jan 1, 2024.","SVP Kevin Brennan granted 20,000 restricted stock units effective same date.","RSUs vest in four equal annual installments beginning Jan 1, 2025, subject to continued service.","Awards granted under 2021 Stock Incentive Plan; form agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266910,"accession_number":"0001558370-23-019579","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xilio initiates Phase 1 combo trial of XTX101 with atezolizumab; reports updated monotherapy data with 33% DCR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated enrollment for Phase 1 dose escalation of XTX101 in combination with atezolizumab; RP2D for combo expected Q2 2024.","Updated monotherapy data at RP2D (150 mg Q6W) show 33% disease control rate in late-line/IO refractory patients; no discontinuations due to TRAE.","Confirmed partial response in PD-L1 negative NSCLC patient continued through 36 weeks with complete resolution of liver metastases.","Plans to initiate Phase 2 trial in MSS CRC in Q3 2024, subject to obtaining sufficient additional capital.","Preliminary PK demonstrates tumor-selective activation: 96% in melanoma, 73% in liver metastasis vs 13% peripheral activation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266909,"accession_number":"0001558370-23-018578","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports Q3 net loss of $16.7M; cash runway into Q2 2024; XTX202 shows 50% DCR at ≥2.8 mg/kg","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.7M vs $19.8M YoY; R&D spend $11.1M, G&A $6.3M.","Cash $59.8M (Sep 30) vs $120.4M (Dec 31); runway into Q2 2024.","XTX202 Phase 1/2: 50% disease control rate at ≥2.8 mg/kg; no vascular leak syndrome.","XTX101: >70% tumor activation in biopsies; clinical trial collaboration with Roche to start combo with atezolizumab in Q4 2023.","XTX301 preliminary Phase 1 safety data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266908,"accession_number":"0001558370-23-017593","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xilio reports XTX202 Phase 1/2 data: 50% disease control at ≥2.8 mg/kg, no vascular leak syndrome","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["62 patients dosed; 42 evaluable for activity: 31% disease control rate (13 SD ≥9 wks) across all doses, 50% at ≥2.8 mg/kg (3/6).","No signs/symptoms of vascular leak syndrome; TRAEs primarily Grade 1-2; no discontinuations due to TRAE.","Two patients on treatment >1 year (MSS CRC and RCC); dose-dependent PK with ~15% activated drug in tumor vs <1% in plasma.","Plan to evaluate XTX202 at 4.0 mg/kg in Phase 2 for melanoma and RCC; initial data expected Q2 2024.","Milestones subject to additional capital: XTX101 combo Phase 2 start Q3 2024, XTX301 data H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284193,"accession_number":"0001558370-23-015426","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Xilio Therapeutics appoints new President, CMO, CDO; Huber resigns to pursue CEO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Huber, M.D., resigns as President and Head of R&D effective Sept 8; remains advisor.","CEO René Russo adds President title; previously served as President in 2021-2022.","Katarina Luptakova promoted to CMO; succeeds Huber with 20 years of oncology drug development experience.","Scott Coleman promoted to CDO; over 25 years in biotech, including at Acceleron and Merck.","Kevin Brennan enters employment agreement (base $370K, 35% bonus target) as SVP Finance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284192,"accession_number":"0001558370-23-014708","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xilio Therapeutics announces Roche collaboration for XTX101 in MSS CRC; cash $75.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered clinical trial collaboration with Roche; Xilio retains rights to XTX101; eligible for cost-sharing payments.","Updated XTX101 data: durable partial response 36 wks in NSCLC; no Grade 4/5 AEs at RP2D; no colitis.","XTX202 cleared 2.8 mg/kg dose, no vascular leak; expects preliminary Phase 1/2 data early Nov 2023 in ≥20 evaluable pts.","Q2 net loss $19.4M vs $24.6M YoY; cash $75.4M, runway into Q2 2024.","Promoted Chris Frankenfield to COO; XTX301 safety data expected Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284191,"accession_number":"0001558370-23-013235","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xilio Therapeutics promotes Christopher Frankenfield to COO; $500k salary, 150k option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Frankenfield promoted from Chief Legal & Admin Officer to COO effective Aug 3, 2023.","New annual base salary of $500,000; target bonus set at 50% of base salary.","Granted option to purchase 150,000 shares of common stock, vesting monthly over 4 years.","Frankenfield previously served as Chief Legal & Admin Officer since Aug 2022 and at Blueprint Medicines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303819,"accession_number":"0001558370-23-011031","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xilio Therapeutics stockholders elect three Class II directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Daniel Curran, Robert Ross, and Yuan Xu elected as Class II directors for three-year terms through 2026.","Ratification of Ernst & Young as independent auditor for FY 2023: 21,955,354 for, 1,623 against, 230,537 abstain.","Broker non-votes of 3,812,216 recorded on each director election.","Annual meeting held June 8, 2023; all proposals passed with strong support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303818,"accession_number":"0001558370-23-010481","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Xilio reports encouraging Phase 1 data for XTX101: partial response in PD-L1 neg NSCLC, favorable safety at RP2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary data from Phase 1 trial of XTX101 in 25 patients with advanced solid tumors; RP2D set at 150 mg Q6W.","Partial response observed at nine weeks in a PD-L1 negative advanced NSCLC patient with hepatic metastases, continuing on treatment.","At RP2D, no Grade 4/5 treatment-related AEs, no colitis or infusion reactions; only Grade 3 AE was diarrhea (resolved).","Evidence of tumor-selective activation: low unmasked drug in peripheral circulation and minimal immune activation in periphery.","Plans to explore XTX101 in combination with PD-(L)1 in immunotherapy-resistant tumor types, including MSI-stable CRC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303817,"accession_number":"0001558370-23-008673","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.","Phase 2 trial started for XTX202 (tumor-activated IL-2) in advanced RCC and melanoma.","R&D expenses $16.1M, up from $14.9M, driven by clinical and manufacturing activities.","Net loss $22.6M vs $21.4M in Q1 2022.","Plan to report preliminary Phase 1 data for XTX101 (anti-CTLA-4) in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303816,"accession_number":"0001558370-23-005393","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Xilio appoints Kevin Brennan as SVP, Finance and Accounting, principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Brennan joined Xilio on March 30, 2023 as SVP, Finance and Accounting and principal financial/accounting officer.","Brennan receives annual base salary of $370,000, target bonus of 35% of base salary.","Granted stock option to purchase 55,000 shares; vests 25% on first anniversary, 75% monthly over 3 years.","Board adopted amended and restated bylaws updating stockholder meeting procedures and universal proxy rules.","Bylaw amendments also include enhanced advance notice disclosure requirements and technical changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":323508,"accession_number":"0001558370-23-002685","cik":1840233,"company_name":"Xilio Therapeutics, Inc.","ticker":"XLO","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.","Net loss for FY2022 was $88.2M vs $75.8M in 2021; Q4 net loss $22.5M vs $19.7M.","XTX202 (tumor-activated IL-2) showed preliminary pharmacodynamic evidence of tumor-selective activation in two patients; no vascular leak syndrome observed.","XTX202 Phase 2 monotherapy trial in melanoma and RCC to initiate April 2023; preliminary Phase 1/2 data expected Q3 2023.","XTX101 (anti-CTLA-4) RP2D set at 150 mg Q6W; preliminary Phase 1 data expected Q2 2023; exploring partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":48940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-03-02T23:59:59+00:00|323508"}